About Halda Therapeutics: A biotechnology company that developed a new class of oral cancer medicines designed to selectively kill tumor cells by turning cancer’s own biology against it.
The old assumption was that cancer’s target had to be blocked
For decades, much of targeted cancer therapy has followed a relatively intuitive idea: find a molecular driver of the disease, then inhibit it. If a protein is helping a tumor grow, the drug should bind to that protein and shut it down. In many cancers, that approach changed the standard of care and gave patients more precise options than older chemotherapy alone.
The limitation is that cancer is not static. Tumors are living systems under pressure. When a drug blocks one route, the disease can develop mutations, amplify the target, activate bypass pathways, or change which signals it depends on. In prostate cancer, for example, therapies that interfere with androgen receptor signaling can be effective for a time, but metastatic castration-resistant disease often finds ways to keep growing despite those interventions.
Why this has been hard
The simplest version of a cancer drug is one that attacks tumor cells and leaves healthy tissue alone. The hard part is that cancer cells are made from the body’s own machinery. They often use the same proteins, pathways, and survival systems normal cells need. A medicine must be powerful enough to matter, selective enough to avoid unacceptable toxicity, and durable enough to stay useful as the tumor changes.
Halda’s work started from a different question: what if the target did not need to be inhibited in the old sense? What if its presence on the cancer cell could be used as an address?
Halda’s different path
In plain English, Halda’s RIPTAC medicines are designed to bring two proteins together inside a cancer cell: one protein that helps identify the tumor cell, and another protein that performs an essential cellular function. By holding those proteins together in a defined way, the medicine is intended to interfere with that essential function selectively in the cancer cell, leading to tumor cell death while sparing cells where the cancer-associated targeting protein is absent or minimally expressed.
The company’s lead program, HLD-0915, is an oral RIPTAC therapy in development for metastatic castration-resistant prostate cancer. It is designed to use the androgen receptor, which remains highly relevant in many prostate tumors, as the tumor-selective targeting protein, and BRD4, a protein involved in transcriptional regulation, as the essential-function protein. Halda has also built programs in breast cancer and other solid tumors, pointing to the broader ambition behind the platform.
Why now
Halda arrived at a moment when induced-proximity science was becoming more than an elegant biological idea. The broader field had already shown that small molecules could be designed to bring proteins together and create new cellular outcomes, as seen in protein degraders and molecular glues. At the same time, oncology was running into the practical limits of therapies that depend mainly on direct inhibition.
That combination mattered. Scientists had better tools for designing heterobifunctional molecules, better understanding of tumor biology, and clearer evidence that resistance was not a side problem but a central problem. The question was whether a company could turn those pieces into a drug modality with a coherent clinical path.
Halda’s answer was to begin with common solid tumors where resistance creates urgent unmet need and where the biology could support selectivity. The early focus on prostate and breast cancer was not incidental. These are large diseases with substantial treatment histories, known molecular features, and patients who need better options after existing therapies stop working.
What makes Halda different
Halda’s distinctiveness is not simply that it works in oncology, or even that it works in induced proximity. The important idea is that the company designed a modality around cancer-selective killing without requiring the cancer target to remain a classic vulnerability.
That is a subtle but meaningful shift. In many therapies, the target must be both present and functionally necessary. Halda’s RIPTAC approach is designed to use a tumor-associated protein as a locator and then create a new interaction that disables an essential function in that tumor cell. If that logic translates clinically, it could open a wider design space for cancers that continue to express useful markers but no longer respond to conventional blockade.
The oral small-molecule format also matters. Cancer care does not happen only in academic centers or specialized infusion clinics. An oral medicine, if proven safe and effective, can fit more naturally into the way many patients already receive care, including in community oncology settings.
Why this matters beyond oncology
For most people, the technical distinction between an inhibitor, a degrader, and a RIPTAC may not matter. What matters is the possibility that cancer drugs can become more adaptive to the ways cancer actually survives.
Patients with advanced disease often live with a brutal sequence: hope, response, resistance, and the search for another option. Families experience cancer not as a pathway diagram but as time gained or lost, symptoms controlled or not, choices remaining or exhausted. Medicines that can work after resistance emerges are not just scientific achievements. They can change the emotional and practical reality of treatment.
The question Halda is asking is not simply whether one oral therapy can help treat advanced prostate cancer. It is whether drug designers can turn cancer’s remaining identifiers into points of attack, even after the disease has learned to escape older approaches.
If Halda’s work succeeds inside Johnson & Johnson, it points toward a future where precision oncology becomes less brittle. Not a world where cancer stops evolving, but one where medicines are designed with that evolution in mind from the beginning. That is the constraint Halda set out to loosen: the idea that once a tumor works around the drug, the drug’s logic has run out. Halda’s deeper contribution is the belief that biology can be reassembled into new therapeutic possibilities, and that resistance, while real, does not have to be the end of the story.